Onconetix (ONCO) Revenue — Quarter Ended Dec 31, 2025
Revenue for the quarter was essentially unchanged from the prior quarter, but declined significantly compared to the same period a year earlier. The company continues to incur operating losses and has raised capital to support its commercialization activities.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue for the quarter was essentially unchanged from the prior quarter, but declined significantly compared to the same period a year earlier. The company continues to incur operating losses and has raised capital to support its commercialization activities.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$303.6K
Revenue reported for this quarter.
Quarter-over-quarter
-0.0%
Change from the immediately preceding quarter.
Year-over-year
-57.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$815.4K
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $101.6K | -85.5% |
| Jun 30, 2025 | $106.5K | -84.9% |
| Sep 30, 2025 | $303.7K | -25.4% |
| Dec 31, 2025 | $303.6K | -57.4% |
Revenue performance
The reported revenue direction was flat sequentially, following a substantial increase in the preceding quarter. Year-over-year, revenue was sharply lower.
Quarterly comparison
Compared to the immediately preceding quarter, revenue was nearly identical. Compared to the same quarter one year earlier, revenue was substantially lower.
What to watch
Monitor whether the company can sustain or grow revenue given its ongoing operating losses and reliance on external financing.